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more (n= 2), and it caused a reduction in glycosylated hemoglobin (HbA1c) (n= 4). 
The impact of TTM on medication adherence is still unknown. ConClusions: TTM 
helps type 2 diabetic patients self-manage their condition, and to reach their goals, 
hence achieving better clinical outcomes, and quality of life.
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objeCtives: To characterise type 2 diabetes (T2DM) patients in the Netherlands 
initiating basal insulin and those intensifying treatment. Methods: Antidiabetic 
dispensing records were obtained from the Out-patient Pharmacy Database of the 
PHARMO Database Network. New users, i.e. first-time dispensing, of basal insu-
lin only were selected between 2007-2012. Treatment intensification was defined 
as either add-on of GLP-1, bolus insulin or DPP-4i or switch to premixed insulin. 
Demographics and HbA1c before basal insulin start (pre-insulin), at intensification 
and post- intensification were assessed including time to intensification. Results: 
A total of 15,986 T2DM patients initiating basal insulin only (median (IQR) age at start 
basal insulin: 65 (55-74) years, 52% male, 87%, 75% and 51% had a pre-insulin HbA1c 
> 53, > 58 and > 64 mmol/mol, respectively). Overall, 4,945 patients (31%) intensified 
treatment during a median follow-up of 14 months (median (IQR) age at start basal 
insulin: 63 (53-73) years, 50% male, 88%, 78% and 54% had an HbA1c at intensifica-
tion > 53, > 58 and > 64 mmol/mol, respectively). Intensification mostly was add-on 
of bolus insulin (58%) or switch to premixed insulin (39%). Median (IQR) time to 
intensification was 8 (2-15) months. Among patients with an HbA1c > 53, > 58 and 
> 64 mmol/mol at intensification, median (IQR) time to intensification was 12 (5-23), 
12 (5-22) and 12 (5-22) months, respectively. Post-intensification, 32%, 52% and 73% 
of the patients attained an HbA1c of ≤ 53, ≤ 58 and ≤ 64 mmol/mol, respectively, 
with median reduction in HbA1c of 6 mmol/mol. ConClusions: About one third 
of T2DM patients initiating basal insulin intensified their treatment leading to gly-
cemic goal attainments of HbA1c ≤ 53, ≤ 58 and ≤ 64 mmol/mol in 32%, 52% and 73% 
of patients, respectively. Further research might provide more information on the 
underlying reasons and potential barriers for intensifying versus not intensifying, 
such as patient characteristics, co-medication, treatment complexity and occur-
rence of hypoglycaemic events.
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objeCtives: To evaluate the clinical and the economic outcomes of a personalized 
care model (PCM) in diabetes mellitus (DM) supported by information and communi-
cations technology (ICT) in the Spanish National Health System (NHS). Methods: 
We evaluated a PCM in DM proposed by a group of European experts based on 6 
steps: 1.Structured education; 2.Structured self-monitoring of blood glucose (SMBG); 
3.Structured documentation; 4.Structured data analysis; 5.Personalized treatment; 
6.Evaluation of results. A literature review was made to assess the results of inter-
ventions made within the NHS that used the PCM described. Interventions evaluat-
ing type 2 DM (T2DM), type 1 DM (T1DM) and gestational DM were included. The 
health outcomes measured were the variation in HbA1c,the percentage of controlled 
patients, the body mass index and the body weight. The analysis was made from the 
payer’s perspective, considering the direct costs related to the pathology (€ 2015). 
Costs evaluated were: hospital costs, outpatient visits costs, primary care costs, 
emergency care costs and SMBG costs. Results: The review carried out showed 
that the introduction of this PCM in T2DM would result in an increase of up to 18% 
in controlled patients (HbA1c% < 7%) compared with the current model (follow-
up of 12 months). The expected reduction in HbA1c%would be about -0.5%. The 
implementation of the PCM proposed would reduce the cost of T2DM by about 12% 
compared with the current model with reductions of up to 30% in the cost for out-
patient visits. The expected reduction in total direct costs was approximately 12% 
in T1DM and around 14% in gestational DM. ConClusions: The implementation 
of a PCM in DM with ICT support improved or provided equal disease control com-
pared with conventional care and reduced the high costs associated with diabetes. 
ICT enables adaption and changes in the current model of care and potentiate 
self-management strategies.
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objeCtives: To identify, describe in detail, and assess the evidence regarding the 
effects of Diabetes Conversation Maps™, an educational tool that engages diabetic 
patients in group discussions about diabetes-related topics, over a range of patient 
outcomes. Methods: We conducted a systematic literature review of articles 
published since 2005 that evaluated the Maps™ since 2005 using five electronic 
databases, and the reference lists of relevant papers. Non-English languages, non-
journal papers, and studies that only included a description of the Maps™ were 
excluded. A quality assessment of relevant studies was performed. Outcomes were 
grouped into: objective (e.g., HbA1c levels), subjective (e.g., self-efficacy), and health 
behaviors (e.g., medication adherence). Results: Of the 62 studies originally identi-
fied, 13 were included in the final sample. The overall methodological quality of the 
sion analysis was employed to assess impact of socioeconomic,demographic and 
disease- specific variables on WTP for QALY. Results: Totally, 149 patients with 
type 1 and 2 diabetes were included in analysis. Types 1 were younger with higher 
probability of hospitalization and longer diabetes duration. Foot diabetic disease, eye 
disease and hypertensive were the main comorbidities in both types, accordingly. 
Mean willingness to pay per QALY were estimated between 58,982,210-124,675,610 
IRR (Iranian Rials) that is equal 2107-4453 US Dollars. Significantly, patients with 
better health state, higher cost group (as a proxy of income) and inpatients admis-
sion had higher WTP for QALY. ConClusions: Mean WTP per QALY are between 
0.44-.93 times of local Gross Domestic Product (GDP) per capita. According to rec-
ommendation of world health organization on using 1-3 time GDP per capita as a 
threshold value and defined cost-effectiveness categories, our findings, although, 
is closed to one, but do not advocate strongly the proposed range by WHO. Thus, in 
decision making and resource allocation process, WHO recommendation should be 
employed with cautious and more investigation.
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objeCtives: Mobile phone SMS is increasingly used as a means of communication 
between patients and their healthcare providers in many countries of the world.We 
investigated mobile phone use and factors associated with willingness-to-pay (WTP) 
for diabetes SMS among patients with type 2 diabetes in Bangladesh. Methods: 
As part of a randomized controlled study, in 515 patients with type 2 diabetes, 
socioeconomic status, mobile phone use, WTP for diabetes SMS, anthropometry and 
HbA1c were measured. Multivariate regression was used to identify factors associ-
ated with WTP. Results: The median (interquartile range [IQR]) of WTP for diabetes 
SMS was 20 (45) Bangladesh Taka (BDT) (1 BDT ¼ 0.013 US$). WTP was significantly 
higher for males [OR 2.4, 95% CI (1.0–5.7)], patients with household income .50 000 
BDT [4.6 (1.1–20.4)] and those with primary education [5.6 (1.2–26.6)] and secondary 
and higher education [5.2 (1.4–19.6)]. ConClusions: The high proportion of mobile 
phone use and WTP for diabetes SMS are encouraging as possible strategy to use 
such technologies and deserve further evaluation.
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objeCtives: The aim of this study was to estimate willingness to pay (WTP) amount 
for one quality adjusted-life years (QALY) in diabetic patients and investigating fac-
tors that associated with it. Methods: A cross sectional survey with face to face 
interviews was conducted with diabetic patients in Tehran city between June and 
August of 2014 to elicit WTP for QALY as following: First, Current health preferences 
were measured using EuroQol-5D (EQ-5D), visual analogue Scale (VAS) and time 
trade off (TTO) techniques, then a hypothetical scenario using double bounded 
dichotomous choice technique was presented to patients to elicit individual’s maxi-
mum WTP for a treatment that recovering them to full health ,contingent to be 
available. So value of QALY was estimated by combining preferences. A regression 
analysis was employed to investigate impact of individuals’ characteristics and 
disease- specific variables on the WTP for QALY. Results: Totally, 149 patients with 
type 1 and 2 diabetes were included in analysis. Types 1 were younger with higher 
probability of hospitalization and longer diabetes duration. Foot diabetic disease, eye 
disease and hypertensive were the main comorbidities in both types, accordingly. 
Mean willingness to pay per QALY were estimated between 58,982,210-124,675,610 
IRR (Iranian Rials) that is equal 2107-4453 US Dollars. Significantly, patients with bet-
ter health state, higher cost group (as a proxy of income) and inpatients admission 
had higher WTP for QALY. ConClusions: Mean WTP per QALY are between 0.44-.93 
times of local Gross Domestic Product (GDP) per capita. According to recommenda-
tion of world health organization on using 1-3 time GDP per capita as a threshold 
value and defined cost-effectiveness categories, our findings, although, is closed to 
one GDP per capita, but do not advocate strongly the proposed range by WHO. Thus, 
in decision making and resource allocation process, WHO recommendation should 
be employed with cautious and more investigation.
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objeCtives: The objective of this study is to assess the use of transtheoretical model 
(TTM) in improving self-management activities in type 2 diabetic patients. Self-
management activities include following a healthier diet, exercising more regularly, 
and an enhanced medication adherence. Methods: Pubmed, Medline, Science 
direct, and Cochrane databases were searched with predefined terms relating to 
TTM interventions for type 2 diabetic patients. All study designs were included. 
The systematic search was conducted in March 2015. Two reviewers independently 
assessed the relevance of abstracts identiﬁed, extracted the data and undertook 
quality analysis. The review was done using PRISMA checklist. Results: Ten studies 
met the criteria for inclusion in the review. All studies demonstrated some positive 
outcomes self-management due to implementing TTM. In six studies the patients 
reached the action or maintenance stage in the TTM cycle after the TTM interven-
tion. Moreover, TTM was able to help patients follow a healthier diet (n= 5), exercise 
A618  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
inappropriate use in 7%-46% of patients. The analysis was limited to drug prescrip-
tion costs and excluded other costs affected by the recommendations, resulting in 
forecasted savings ranging from $7-$16 million over a 3-year period. JSS Medical 
Research performed the BIA from the ministry of health perspective. Methods: 
Our hybrid epidemiological and claims-based BIA included costs of TRTs and key 
cost drivers of physician visits, administering injectable TRTs, testosterone level 
testing and Exceptional Access Program evaluation and processing. Ontario pre-
scription drug expenditures based on claims data, as well as published literature 
and expert opinion were utilized. We evaluated the impact of the ODPRN scenarios 
with and without inappropriate TRT use over a 3-year period. Results: Based on 
the JSS assumption of all patients qualifying for TRT and taking into consideration 
key cost drivers, option B would cost $1.01 million; option C $766,000, and option D 
$252,000. Using ODPRN assumptions of inappropriate use, JSS forecasted savings 
of $373,000-$13.4 million as opposed to savings of $7-$16 million forecasted by 
the ODPRN. ConClusions: ODPRN savings exclude key cost drivers and assume 
a greater magnitude of inappropriate use. The burden of the policy change could 
completely offset savings and generate costs of up to $1 million to the healthcare 
budget. Healthcare policy recommendations based on drug costs alone underesti-
mate the true cost, shifting and in this case creating additional costs to other areas 
of the healthcare system.
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objeCtives: Treatment guidelines propose stepwise approach for type II diabe-
tes management: metformin (Met) as first, Met + SUs or other oral antidiabetic 
agents (i.e. DPP4s) or insulin as second or third line. Despite this evidence based 
line treatment, DPP4s prescriptions in Turkey can be initiated only by endocrinol-
ogy or internal medicine specialists working on tertiary care since March 2010 to 
control DM treatment budget. This access restriction may naturally cause prescrip-
tion shifts to non-restricted treatment options such as insulins. This research’s 
objective is comparing yearly usage ratio of insulins and DPP4s in Turkey and 5 
European Turkey’s price reference countries. Methods: Sales as international 
units(IU) and value between 2010-2014 are obtained from IMS Dataview7. Yearly 
total insulin vs. DPP4s as IU/SU and US$ sales is compared between Turkey and 
France, Greece, Italy, Portugal, Spain. Results: Insulin to DPP4s utilization ratio 
in Turkey(183) is 4,6 times higher than reference countries’ average (40) in 2014. 
Compared to 5 EU countries, total insulin to DPP4s utilization ratio is consist-
ently the highest (540 in 2010 and 183 in 2014) in Turkey between 2010-2014. As 
value sales, the highest ratio of total insulin to DPP4s is in Turkey (7,2), followed 
by Italy(2,9) and France(1,3). In Portugal, Spain and Greece this ratio is below one, 
indicating higher DPP4 value sales compared to insulins. Reversed ratio of insulin 
to DPP4s in Turkey is also present between 2010-2013. ConClusions: Turkey has 
the highest insulin to DPP4 ratio over five years among other countries. DPP4s 
access restriction might have caused early and disproportionate insulinization 
of patients. From health policy perspective, implementation of access restriction 
might have led cost reduction in the short run, however it may cause greater 
burden due to shifts to later treatment lines.
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objeCtives: Diabetes is a chronic condition for which effective medications must 
be taken continuously (i.e. patient must be observant). Research shows that intro-
ducing user fees may reduce patient observance. However, there is little evidence 
that providing free medications improves diabetic patient observance. Taking advan-
tage of a change in Quebec (Canada) policy the objective of this study was to assess 
whether the return to free medications (RFM) improved diabetic patient obser-
vance. Methods: This study used a pretest-posttest design: drug use by diabetic 
patients in the 3 years prior to RFM was compared to their drug use in the 2 years 
following RFM. Data came from the Quebec public drug plan (QPDP) for three groups: 
social welfare recipients, elderly receiving full guaranteed revenue supplement (GRS) 
and those receiving partial GRS. Data on oral antidiabetic drug consumption were 
obtained for a random sample of patients that were covered by the QPDP during the 
full five year period (N total = 3308). Two indicators of observance were measured: 
whether a patient was using antidiabetic drugs at least 80% of days and the propor-
tion of days where antidiabetic drugs were used. These were measured both for the 
12 months following the first prescription prior to RFM and after RFM and for the 
whole pre-RFM and post-RFM periods. To compare pre and post RFM data, we used 
Chi-square test for the first indicator and t-test for the second indicator. Results: 
The proportion of patients who were observant was significantly (p< 0.001) higher 
after RFM compared to before RFM, both for 12 months (87.3% vs. 82.8%) and the 
whole period (85.3% vs. 83.7%). The proportion of days where antidiabetic drugs were 
used also was significantly higher (92.3% vs. 89.2%; 90.8% vs 86.6%). ConClusions: 
Providing free medications to diabetic patients raised their observance and may 
have improved patient outcomes.
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objeCtives: According to the literature, there is a gap between the results of clini-
cal trials (efficacy) and the effects of the same intervention in real-life (effective-
ness). Although this so-called “efficacy-effectiveness gap” is often mentioned in 
studies was intermediate (score: 17 of 28). Almost all studies examined objective 
health measures, with most indicating non-significant differences between the 
Maps™ intervention and the control group/s. Mixed results were found regarding 
the influence on HbA1c. The majority of studies reported no significant change in 
blood pressure and mixed results were found regarding other health indicators. Only 
five studies examined subjective measures and eight assessed the effects on health 
behaviors, mostly reporting non-significant or positive findings. ConClusions: 
This review provides evidence about the limited number and relatively low quality 
of studies, which examined the influence of Maps™ on health outcomes. Although 
Maps™ hold the potential to improve health outcomes, there is a need to develop 
well-designed large sample studies that enable to draw more conclusive results.
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objeCtives: Type 1 diabetes mellitus (T1DM) affects approximately 400,000 people 
in the UK, amounting to £1.8 billion in direct healthcare costs in 2012. Statistics 
from the 2012/13 national diabetes audit (NDA) suggest that 92.4% of T1DM patients 
in England fail to achieve target haemoglobin A1c (HbA1c) levels (< 48 mmol/mol 
[6.5%]). Current NICE draft guidance recognises the importance of education on 
glycaemic control; recommending courses for all T1DM patients within one year of 
diagnosis. However, only 4.1% of newly-diagnosed diabetics are offered structured 
courses such as the Dose Adjustment for Normal Eating (DAFNE). We sought to 
determine the relationship between educational course availability and uptake, 
and target HbA1c achievement. Methods: Educational course attendance data 
and HbA1c results for T1DM patients was extracted from the 2012/13 NDA for 9 
regions in England, and DAFNE centre location records for 2014 were obtained. We 
explored the relationship between educational course uptake and optimal HbA1c 
achievement in newly-diagnosed patients, and also the number of DAFNE cen-
tres against overall T1DM HbA1c achievement. Results: Newly-diagnosed T1DM 
patients consistently manage HbA1c better than the overall T1DM population. 
However, no association was found between education course uptake or the number 
of DAFNE centres per region, and optimal HbA1c achievement in newly-diagnosed 
patients. A weak positive correlation was found between the number of DAFNE 
locations, and patients in the overall T1DM population achieving optimal HbA1c 
(R2= 0.3). ConClusions: Educational courses may help T1DM patients achieve bet-
ter glycaemic control. However, uptake for courses is below current NICE draft rec-
ommendations. Increasing uptake for such courses could help improve target HbA1c 
achievement in the long-term, whilst also providing a societal benefit through cost 
savings. Examining potential socio-economic factors and their impact on course 
uptake could be investigated. More research is required into educational course 
uptake in the overall T1DM population.
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objeCtives: As the number of people with diabetes grows worldwide, it becomes 
a challenging problem for public health budgets. The objective of this study is to 
investigate and analyze the main characteristics of diabetes in Turkey. Methods: 
Claims data from Turkish Social Security Institution were collected for the diagnosed 
patients having insulin dependent (IDD) and non-insulin dependent diabetes (NIDD) 
between 2010 and 2014. Prevalence, incidence, age and gender distribution, and 
mortality figures were aggregated and analyzed in order to show how the disease is 
evolving. Results: Number of patients diagnosed with diabetes between 2010 and 
2014 totaled 3.1 million; nearly 85% with NIDD and 60% were females. On average 
645,000 new patients were added yearly. The incidence of diabetes dropped from 
0.94% to 0.76% in 2010-2014, where IDD and NIDD were 0.06% and 0.71% in 2014 
respectively. While the share of NIDD patients represented 81% in 2010, the figure 
hiked 90% in 2014. When it comes to age distribution, 46-64 age group received 
the largest share (48%) among all patients, followed by 25-45 and 65+ age groups, 
all three constituting nearly 96%. The average age of first diagnosis for male and 
female were 58.6 and 59.4 respectively, signaling that the disease is late diagnosed 
compared to other countries. In addition, 21% of females and %14 of males died 
over four-year time and average age of death was nearly the same in both diabetes 
types. ConClusions: Despite the decline in the incidence, diabetes epidemic is 
expected to grow in the future with lower mortality rates. Late diagnosis of diabe-
tes seems to be the most important problem in Turkey. Then, immediate action is 
needed for new strategies such as yearly monitoring and public education programs 
to reach out patients earlier.
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objeCtives: The Ontario Drug Policy Research Network (ODPRN) published recom-
mendations to restrict reimbursement and coverage criteria of testosterone replace-
ment therapy (TRT) in Ontario. The ODPRN’s budget impact analysis (BIA) evaluated: 
no reimbursement change (option A), restricting coverage of all forms of TRT (option 
B), restricting oral and topical forms only (option C), or restricting topical forms 
only (option D). The analysis assumed exponential growth of TRT expenditures and 
